Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Plasma growth differentiation factor 15 levels for predicting serious adverse events and bleeding in acute pulmonary embolism: a prospective observational study.

Tytuł:
Plasma growth differentiation factor 15 levels for predicting serious adverse events and bleeding in acute pulmonary embolism: a prospective observational study.
Autorzy:
Skowrońska M; Department of Internal Medicine and Cardiology with the Centre for Management of Venous Thromboembolic Disease, Medical University of Warsaw, Warsaw, Poland. />Skrzyńska M; Department of Internal Medicine and Cardiology with the Centre for Management of Venous Thromboembolic Disease, Medical University of Warsaw, Warsaw, Poland
Machowski M; Department of Internal Medicine and Cardiology with the Centre for Management of Venous Thromboembolic Disease, Medical University of Warsaw, Warsaw, Poland
Bartoszewicz Z; Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Warsaw, Poland
Paczyńska M; Department of Internal Medicine and Cardiology with the Centre for Management of Venous Thromboembolic Disease, Medical University of Warsaw, Warsaw, Poland
Ou-Pokrzewińska A; Department of Internal Medicine and Cardiology with the Centre for Management of Venous Thromboembolic Disease, Medical University of Warsaw, Warsaw, Poland
Kurnicka K; Department of Internal Medicine and Cardiology with the Centre for Management of Venous Thromboembolic Disease, Medical University of Warsaw, Warsaw, Poland
Ciurzyński M; Department of Internal Medicine and Cardiology with the Centre for Management of Venous Thromboembolic Disease, Medical University of Warsaw, Warsaw, Poland
Roik M; Department of Internal Medicine and Cardiology with the Centre for Management of Venous Thromboembolic Disease, Medical University of Warsaw, Warsaw, Poland
Wiśniewska M; 1st Department of Radiology, Medical University of Warsaw, Warsaw, Poland
Palczewski P; 1st Department of Radiology, Medical University of Warsaw, Warsaw, Poland
Pruszczyk P; Department of Internal Medicine and Cardiology with the Centre for Management of Venous Thromboembolic Disease, Medical University of Warsaw, Warsaw, Poland
Źródło:
Polish archives of internal medicine [Pol Arch Intern Med] 2020 Sep 30; Vol. 130 (9), pp. 757-765. Date of Electronic Publication: 2020 Jul 16.
Typ publikacji:
Journal Article; Observational Study
Język:
English
Imprint Name(s):
Original Publication: Liszki, Poland : Medycyna Praktyczna, [2017]-
MeSH Terms:
Growth Differentiation Factor 15*
Pulmonary Embolism*/diagnosis
Acute Disease ; Humans ; Plasma ; Prospective Studies
Substance Nomenclature:
0 (Growth Differentiation Factor 15)
Entry Date(s):
Date Created: 20200721 Date Completed: 20210427 Latest Revision: 20220531
Update Code:
20240104
DOI:
10.20452/pamw.15515
PMID:
32686380
Czasopismo naukowe
Introduction: Growth differentiation factor 15 (GDF‑15), a cytokine induced in the myocardium by pressure overload and ischemia, has a well‑established prognostic role for diseases of the left ventricle. Plasma GDF‑15 concentrations were shown to predict bleeding events in patients with atrial fibrillation on anticoagulation.
Objectives: To investigate the prognostic value of GDF‑15 in acute pulmonary embolism (PE).
Patients and Methods: This was a prospective observational study of 77 patients hospitalized for PE. The median length of hospital stay and follow-up was 9 days. Plasma GDF‑15 levels were measured using an automated sandwich electrochemiluminescence immunoassay. The outcome measures were: 1) in‑hospital serious adverse events (SAE; death, cardiopulmonary resuscitation, need for urgent reperfusion therapy, catecholamine administration), and 2) major bleeding or nonmajor clinically relevant bleeding.
Results: There were 12 SAE and 5 bleeding events. The median (interquartile range) GDF‑15 concentration at admission was 2354 ng/l (1151-4750 ng/l). GDF‑15 concentrations increased according to risk subgroup. Patients with serious adverse events or bleeding events had higher baseline concentrations of GDF‑15 (median [interquartile range], 3460 ng/l [2 531-12 363 ng/l] vs 2034 ng/l [1121-4449 ng/l]; P = 0.01). The area under the curve for GDF‑15, high‑sensitivity cardiac troponin T, and N‑terminal pro-brain natriuretic peptide concentrations for predicting SAE was similar, the area under the curve of GDF‑15 levels for predicting bleeding was 0.783 (95% CI, 0.62-0.946; P = 0.001) and 0.71 (95% CI, 0.567-0.853; P = 0.004) for predicting any adverse event. In the multivariable analysis, GDF‑15 greater than 1680 ng/l emerged as an independent predictor of adverse outcomes (odds ratio, 8.9; P = 0.047).
Conclusions: Plasma GDF‑15 concentrations may be a promising biomarker for predicting hemodynamic destabilization and bleeding complications in PE.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies